SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly results and outlook sparked volatile trading: strong advertising growth and revenue guidance drew bullish reactions, while heavy AI infrastructure spending, negative free cash flow, a legal charge and the new non-voting share structure fueled concerns about returns and dilution. The debate centers on whether AI and ad gains can justify the spending, with some traders viewing the selloff as an overreaction.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias Q3 results beat expectations, with strong AI and cloud growth and higher customer orders, but traders are frustrated that the shares have struggled despite the positive report. The debate centers on whether that demand will translate into sustained revenue and cash flow, with restructuring costs and a weak share-price response tempering bullish views.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius new Citi financing facility and GTC Berlin comments on strong AI-compute demand have put its funding needs and growth plans in focus. Traders are split on whether added financing helps the company expand capacity or increases debt risk, while some point to managements account of customer prepayments and a funding model they see as less exposed than peers.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY discussion centers on volatile selling tied to worries that big-tech earnings and heavy AI spending may not justify the investment, with traders also pointing to Iran tensions and elevated oil prices as added risk. The community is split between expecting further downside and buying a rebound; cyberattack concerns also appear, but are discussed speculatively.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure as traders weigh Meta and Tesla results against renewed concerns about AI spending and returns: Meta raised its investment outlook while Tesla cut its capex target. The community is split between dip-buyers anticipating a rebound and bears warning of a broader tech selloff, with Iran-related oil and market risks adding to volatility.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are driving discussion as shares weaken, with traders weighing whether AI and Cloud growth can offset heavy AI spending and threats to Search advertising from competing AI products. Bears expect further downside if the outlook disappoints, while bulls are buying the dip and anticipating strong results.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas quarterly results drove a mixed reaction: adjusted earnings and cash flow beat expectations, but flat revenue, weaker operating profit, reduced capital-spending guidance, and a slower Optimus ramp fueled concerns about growth and execution. Bulls highlighted improved auto margins and the AI, FSD, and robotics opportunity, while bears questioned profitability and the valuation.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

The FDA accepted Biohavens resubmitted NDA for troriluzole (VYGLXIA) for spinocerebellar ataxia, setting a Q1 2027 goal date after an earlier rejection. Traders welcomed the regulatory progress, while debating the drugs commercial potential, the remaining approval uncertainty, and whether the news-driven move could give way to profit-taking.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is drawing attention after beating quarterly expectations, raising its annual outlook, and reporting a record backlog tied in part to strong missile demand. The reaction is mostly bullish, though some traders remain cautious about execution, margins, and F-35 funding.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBMs quarterly results beat expectations, with stronger software growth and an improved cash-flow outlook, but shares gave back their initial post-report gains. Traders are debating whether the reversal reflects profit-taking and high expectations or concerns about softer margins, weak consulting growth, and clients scrutinizing AI spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insmed Appoints Two New Directors to Its Board

Insmed Appoints Two New Directors to Its Board Insmed Appoints Two New Directors to Its BoardPR NewswireBRIDGEWATER, N.J., Oct. 20, 2026 Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New...

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know 

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in 2015 and is headquartered in Watertown, MA.

C4 Therapeutics Inc

CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>C4&nbsp;Therapeutics is also eligible to earn tiered royalties on future product sales.</li><li>C4 and Roche will focus on developing emerging cancer treatments using degrader-antibody conjugates and targeted protein degradation processes.</li><li>The companies will work together on two programs to develop the new cancer treatments.&nbsp;</li></ul>Shares of C4 Therapeutics, Inc. (CCCC) reversed pre-market gains to edge 2% lower on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer treatments.C4 Therapeutics said the new collaboration will focus on developing emerging cancer treatments using&nbsp;a degrader-antibody conjugate (DAC) and targeted protein degradation (TPD) processes.&nbsp;“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding. Together, these capabilities build a powerful new modality that can offer transformative medicines for patients,” said Andrew Hirsch, President and CEO of C4 Therapeutics.<h2 class="st-heading-2">C4 Could Earn Up To $1 Billion</h2>The companies will work together on two programs to develop new cancer treatments. C4&nbsp;Therapeutics&nbsp;will design the drug components using its TORPEDO platform, which uses advanced tools and AI to target harmful proteins.&nbsp;&nbsp;Roche will create the antibodies and combine them with the drug. Roche will also handle testing, development, and sales.&nbsp;C4&nbsp;Therapeutics&nbsp;will receive a $20 million upfront payment for the two programs, with the potential for additional payments if Roche opts to include a third target. The agreement also includes near-term discovery milestones, while total milestone payments could exceed $1 billion. Additionally, the firm is eligible to earn tiered royalties on future product sales.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the reversal after the opening bell, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/CCCC">CCCC</a> flipped to ‘extremely bullish’ from&nbsp; ‘bearish’ a day earlier, amid ‘high’ message volumes.One user said that, based on the contract, the stock should be around $4 to $5. It is currently around $2.8.<stembedurl>https://stocktwits.com/intrader/message/649802478</stembedurl>Another bullish user highlighted the company’s runway until 2028.<stembedurl>https://stocktwits.com/intrader/message/649810594</stembedurl>The stock has shot up more than 35% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.

Roche Holdings AG ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.17
Prev Close	$3.16
Open	$3.15
Dividend Yield	0.00%
50-Day Moving Average	$3.45
Beta	2.00
Avg. Volume	2.07M
PE Ratio	-3.17

52-Week High	$5.17
52-Week Low	$1.69
Market Capitalization	$388.76M
EPS (Annual)	-$1.27
Price to Book	1.58
Revenue Per Employee	$345,644.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

CCCC Fundamentals